X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
bibw 2992 (106) 106
oncology (100) 100
index medicus (94) 94
humans (88) 88
afatinib (83) 83
open-label (50) 50
female (45) 45
gefitinib (44) 44
egfr (43) 43
quinazolines - therapeutic use (40) 40
acquired-resistance (39) 39
cell lung-cancer (38) 38
cancer (36) 36
erbb family blocker (36) 36
pharmacology & pharmacy (36) 36
middle aged (34) 34
tyrosine kinase inhibitor (34) 34
chemotherapy (33) 33
lung neoplasms - drug therapy (33) 33
growth-factor receptor (32) 32
receptor, epidermal growth factor - antagonists & inhibitors (32) 32
1st-line treatment (31) 31
erlotinib (31) 31
male (31) 31
afatinib bibw 2992 (30) 30
carcinoma, non-small-cell lung - drug therapy (30) 30
protein kinase inhibitors - therapeutic use (30) 30
aged (29) 29
adult (27) 27
quinazolines - adverse effects (27) 27
care and treatment (26) 26
epidermal growth factor (26) 26
lung cancer, non-small cell (26) 26
mutation (26) 26
antineoplastic agents - therapeutic use (25) 25
egfr mutations (25) 25
quinazolines - administration & dosage (25) 25
adenocarcinoma (24) 24
medicine & public health (24) 24
lung cancer (23) 23
research (23) 23
tyrosine kinase inhibitors (23) 23
non-small cell lung cancer (21) 21
pharmacokinetics (21) 21
phase-i (21) 21
trial (21) 21
tumors (21) 21
epidermal growth factor receptor (20) 20
neoplasms - drug therapy (20) 20
phase-ii trial (20) 20
quinazolines - pharmacokinetics (20) 20
receptor, erbb-2 - antagonists & inhibitors (20) 20
animals (19) 19
tyrosine kinase (19) 19
treatment outcome (18) 18
antineoplastic combined chemotherapy protocols - therapeutic use (17) 17
pharmacology/toxicology (17) 17
protein kinase inhibitors - pharmacology (17) 17
quinazolines - pharmacology (17) 17
tyrosine (17) 17
antineoplastic agents - pharmacology (16) 16
hematology, oncology and palliative medicine (16) 16
inhibitor (16) 16
lung neoplasms - genetics (16) 16
breast cancer (15) 15
drug therapy (15) 15
health aspects (15) 15
receptor, epidermal growth factor - genetics (15) 15
aged, 80 and over (14) 14
antimitotic agents (14) 14
antineoplastic agents (14) 14
carcinoma, non-small-cell lung - genetics (14) 14
lung-cancer (14) 14
antineoplastic combined chemotherapy protocols - adverse effects (13) 13
cancer research (13) 13
maximum tolerated dose (13) 13
mutations (13) 13
nsclc (13) 13
phase i (13) 13
receptor, epidermal growth factor - metabolism (13) 13
receptor, erbb-2 - metabolism (13) 13
resistance (13) 13
solid tumors (13) 13
advanced solid tumors (12) 12
analysis (12) 12
breast neoplasms - drug therapy (12) 12
her2 (12) 12
i dose-escalation (12) 12
kinases (12) 12
lung neoplasms - pathology (12) 12
metastasis (12) 12
previously treated patients (12) 12
protein kinase inhibitors - adverse effects (12) 12
carcinoma, non-small-cell lung - pathology (11) 11
dose-response relationship, drug (11) 11
drug resistance, neoplasm (11) 11
egf receptor (11) 11
neoplasms (11) 11
pharmacology (11) 11
respiratory tract diseases (11) 11
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Revue de Pneumologie Clinique, ISSN 0761-8417, 10/2014, Volume 70, Issue 5, pp. 279 - 285
Afatinib (BIBW 2992) is an irreversible multi-target HER receptor tyrosine kinase inhibitor developed in patients with advanced solid tumours. Several phase I... 
BIBW 2992 | Afatinib | Tyrosine kinase inhibitor | Lung cancer | EGFR
Journal Article
Journal Article
British Jounal of Cancer, ISSN 0007-0920, 01/2008, Volume 98, Issue 1, pp. 80 - 85
To assess tolerability, pharmacokinetics ( PK), pharmacodynamics ( PD) and clinical activity of the dual epidermal growth factor receptor ( EGFR) 1 and 2 (... 
BIBW 2992 | PROTEIN | SAFETY | epidermal growth factor receptor | pharmacokinetics | MALIGNANCIES | phase I | tyrosine kinase inhibitor | CANCER | UMCG Approved | ONCOLOGY
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 4/2012, Volume 69, Issue 4, pp. 891 - 899
This Phase I study determined the maximum-tolerated dose (MTD) of afatinib (Afatinib is an investigational compound and its safety and efficacy have not yet... 
BIBW 2992 | Phase I | Medicine & Public Health | Afatinib | Tyrosine kinase inhibitor | Non-small cell lung cancer | Cancer Research | Oncology | Pharmacology/Toxicology | Epidermal growth factor receptor | GEFITINIB | TYROSINE KINASE | EGFR | TRIAL | ONCOLOGY | EGFR/HER2 INHIBITOR | PHARMACOLOGY & PHARMACY | MUTATIONS | RECEPTORS | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Lung Neoplasms - enzymology | Humans | Middle Aged | Male | Protein Kinase Inhibitors - adverse effects | Dose-Response Relationship, Drug | Maximum Tolerated Dose | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Adult | Female | Quinazolines - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Tyrosine | Medical research | Medical colleges | Care and treatment | Lung cancer | Oncology, Experimental | Research | Lung cancer, Non-small cell | Antineoplastic agents | Antimitotic agents | Complications and side effects | Chemotherapy | Enzyme inhibitors | Epidermal growth factor | Erlotinib | Analysis | Medicine, Experimental | Skin | Gefitinib | Tumors | Cancer | Index Medicus
Journal Article
Journal Article
Future Oncology, ISSN 1479-6694, 07/2011, Volume 7, Issue 7, pp. 817 - 825
Afatinib (BIBW 2992), a novel aniline-quinazoline derivative, irreversibly and equipotently targets the intrinsic kinase activity of all active ErbB receptor... 
afatinib | BIBW 2992 | EGFR/HER2 | TKI | NSCLC | GEFITINIB | TYROSINE KINASE | FAILURE | EGFR | TRIAL | THERAPY | ONCOLOGY | EGFR/HER2 INHIBITOR | HER2 | IRREVERSIBLE INHIBITOR
Journal Article
Investigational New Drugs, ISSN 0167-6997, 6/2013, Volume 31, Issue 3, pp. 734 - 741
Background A phase I study to assess the maximum tolerated dose (MTD) of a short course of afatinib in combination with docetaxel for the treatment of solid... 
BIBW 2992 | Phase I | Medicine & Public Health | Afatinib | Tyrosine kinase inhibitor | Oncology | Pharmacology/Toxicology | Pharmacokinetics | Epidermal growth factor receptor | GEFITINIB | CARBOPLATIN | KINASE INHIBITOR | BIBW-2992 | LINES | PACLITAXEL | CELL LUNG-CANCER | TRIAL | ONCOLOGY | PHARMACOLOGY & PHARMACY | ERLOTINIB | Skin Diseases - chemically induced | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Drug Administration Schedule | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Quinazolines - pharmacokinetics | Male | Antineoplastic Agents - administration & dosage | Neoplasms - drug therapy | Taxoids - pharmacokinetics | Taxoids - administration & dosage | Maximum Tolerated Dose | Neoplasms - blood | Antineoplastic Agents - adverse effects | Quinazolines - adverse effects | Adult | Female | Quinazolines - administration & dosage | Aged | Antineoplastic Agents - pharmacokinetics | Gastrointestinal Diseases - chemically induced | Taxoids - adverse effects | Antimitotic agents | Complications and side effects | Patient outcomes | Dosage and administration | Research | Drug therapy, Combination | Antineoplastic agents | Drug therapy | Tumors | Studies | Medical research | Prescription drugs | Chemotherapy | Statistical analysis | Research & development--R&D | Pharmacology | Cancer therapies | Index Medicus | Phase I Studies
Journal Article
STRAHLENTHERAPIE UND ONKOLOGIE, ISSN 0179-7158, 05/2007, Volume 183, Issue 5, pp. 256 - 264
Journal Article
Strahlentherapie und Onkologie, ISSN 0179-7158, 5/2007, Volume 183, Issue 5, pp. 256 - 264
Journal Article
Journal Article
Annals of Oncology, ISSN 0923-7534, 03/2019, Volume 30, Issue 3, pp. 447 - 455
Abstract Background Effective targeted therapy for non-small-cell lung cancer (NSCLC) patients with human epidermal growth factor receptor 2 (HER2) mutations... 
clinical trial | BIBW 2992 | DOMAIN | DRIVERS | HER2 mutations | EGFR | pyrotinib | TRIAL | ONCOLOGY | patient-derived organoids | NERATINIB | MUTATIONS | AFATINIB | PHASE-I | non-small-cell lung cancer
Journal Article